225 related articles for article (PubMed ID: 30306637)
1. Inflammation is a potential risk factor of voriconazole overdose in hematological patients.
Gautier-Veyret E; Truffot A; Bailly S; Fonrose X; Thiebaut-Bertrand A; Tonini J; Cahn JY; Stanke-Labesque F
Fundam Clin Pharmacol; 2019 Apr; 33(2):232-238. PubMed ID: 30306637
[TBL] [Abstract][Full Text] [Related]
2. Variability of voriconazole plasma concentrations after allogeneic hematopoietic stem cell transplantation: impact of cytochrome p450 polymorphisms and comedications on initial and subsequent trough levels.
Gautier-Veyret E; Fonrose X; Tonini J; Thiebaut-Bertrand A; Bartoli M; Quesada JL; Bulabois CE; Cahn JY; Stanke-Labesque F
Antimicrob Agents Chemother; 2015 Apr; 59(4):2305-14. PubMed ID: 25645831
[TBL] [Abstract][Full Text] [Related]
3. Optimization of voriconazole therapy for treatment of invasive aspergillosis: Pharmacogenomics and inflammatory status need to be evaluated.
Gautier-Veyret E; Thiebaut-Bertrand A; Roustit M; Bolcato L; Depeisses J; Schacherer M; Schummer G; Fonrose X; Stanke-Labesque F
Br J Clin Pharmacol; 2021 Jun; 87(6):2534-2541. PubMed ID: 33217017
[TBL] [Abstract][Full Text] [Related]
4. Different effects of lansoprazole and rabeprazole on the plasma voriconazole trough levels in allogeneic hematopoietic cell transplant recipients.
Yasu T; Konuma T; Kato S; Kurokawa Y; Takahashi S; Tojo A
Ann Hematol; 2016 Oct; 95(11):1845-51. PubMed ID: 27535751
[TBL] [Abstract][Full Text] [Related]
5. Predictive Value of FMO3 Variants on Plasma Disposition and Adverse Reactions of Oral Voriconazole in Febrile Neutropenia.
Wang X; Zhao J; Wen T; Liao X; Luo B
Pharmacology; 2021; 106(3-4):202-210. PubMed ID: 32998136
[TBL] [Abstract][Full Text] [Related]
6. A retrospective, multicenter study of voriconazole trough concentrations and safety in patients with Child-Pugh class C cirrhosis.
Wang T; Yan M; Tang D; Xue L; Zhang T; Dong Y; Zhu L; Wang X; Dong Y
J Clin Pharm Ther; 2018 Dec; 43(6):849-854. PubMed ID: 29893015
[TBL] [Abstract][Full Text] [Related]
7. Impact of CYP2C19 Genotype and Drug Interactions on Voriconazole Plasma Concentrations: A Spain Pharmacogenetic-Pharmacokinetic Prospective Multicenter Study.
Blanco-Dorado S; Maroñas O; Latorre-Pellicer A; Rodríguez Jato MT; López-Vizcaíno A; Gómez Márquez A; Bardán García B; Belles Medall D; Barbeito Castiñeiras G; Pérez Del Molino Bernal ML; Campos-Toimil M; Otero Espinar F; Blanco Hortas A; Durán Piñeiro G; Zarra Ferro I; Carracedo Á; Lamas MJ; Fernández-Ferreiro A
Pharmacotherapy; 2020 Jan; 40(1):17-25. PubMed ID: 31782536
[TBL] [Abstract][Full Text] [Related]
8. Impact of flavin-containing monooxygenase 3 and CYP2C19 genotypes on plasma disposition and adverse effects of voriconazole administered orally in immunocompromised patients.
Yamada T; Mino Y; Naito T; Kawakami J
J Infect Chemother; 2019 Dec; 25(12):1019-1025. PubMed ID: 31239195
[TBL] [Abstract][Full Text] [Related]
9. Voriconazole-related severe adverse events: clinical application of therapeutic drug monitoring in Korean patients.
Kim SH; Yim DS; Choi SM; Kwon JC; Han S; Lee DG; Park C; Kwon EY; Park SH; Choi JH; Yoo JH
Int J Infect Dis; 2011 Nov; 15(11):e753-8. PubMed ID: 21831685
[TBL] [Abstract][Full Text] [Related]
10. Impact of CYP2C19 Genotype and Liver Function on Voriconazole Pharmacokinetics in Renal Transplant Recipients.
Li ZW; Peng FH; Yan M; Liang W; Liu XL; Wu YQ; Lin XB; Tan SL; Wang F; Xu P; Fang PF; Liu YP; Xiang DX; Zhang BK
Ther Drug Monit; 2017 Aug; 39(4):422-428. PubMed ID: 28604474
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic drug monitoring of voriconazole and CYP2C19 phenotype for dose optimization in paediatric patients.
Hu L; Huang Q; Huang S; Feng Z
Eur J Clin Pharmacol; 2023 Sep; 79(9):1271-1278. PubMed ID: 37458772
[TBL] [Abstract][Full Text] [Related]
12. Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections.
Pascual A; Csajka C; Buclin T; Bolay S; Bille J; Calandra T; Marchetti O
Clin Infect Dis; 2012 Aug; 55(3):381-90. PubMed ID: 22610925
[TBL] [Abstract][Full Text] [Related]
13. Combined impact of hypoalbuminemia and pharmacogenomic variants on voriconazole trough concentration: data from a real-life clinical setting in the Chinese population.
Li Y; Zhang Y; Zhao J; Bian J; Zhao Y; Hao X; Liu B; Hu L; Liu F; Yang C; Feng Y; Huang L
J Chemother; 2024 May; 36(3):179-189. PubMed ID: 37599449
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic drug monitoring and safety of voriconazole in elderly patients.
Cheng L; Xiang R; Liu F; Li Y; Chen H; Yao P; Sun F; Xia P
Int Immunopharmacol; 2020 Jan; 78():106078. PubMed ID: 31830620
[TBL] [Abstract][Full Text] [Related]
15. Voriconazole therapeutic drug monitoring: Factors associated with supratherapeutic and subtherapeutic voriconazole concentrations.
You H; Dong Y; Zou Y; Zhang T; Lei J; Chen L; Wang X; Dong Y; Wang T
Int J Clin Pharmacol Ther; 2018 May; 56(5):239-246. PubMed ID: 29393850
[TBL] [Abstract][Full Text] [Related]
16. Voriconazole therapeutic drug monitoring in critically ill patients improves efficacy and safety of antifungal therapy.
Li H; Li M; Yan J; Gao L; Zhou L; Wang Y; Li Q; Wang J; Chen T; Wang T; Zheng J; Qiang W; Zhang Y; Shi Q
Basic Clin Pharmacol Toxicol; 2020 Dec; 127(6):495-504. PubMed ID: 32639669
[TBL] [Abstract][Full Text] [Related]
17. Impact of dose adaptations following voriconazole therapeutic drug monitoring in pediatric patients.
Lempers VJ; Meuwese E; Mavinkurve-Groothuis AM; Henriet S; van der Sluis IM; Hanff LM; Warris A; Koch BCP; Brüggemann RJ
Med Mycol; 2019 Nov; 57(8):937-943. PubMed ID: 30759261
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetic model-guided optimization of intravenous voriconazole dosing regimens in critically ill patients with liver dysfunction.
Lin XB; Lui KY; Guo PH; Liu XM; Liang T; Hu XG; Tong L; Wu JJ; Xia YZ; Chen P; Zhong GP; Chen X; Cai CJ
Pharmacotherapy; 2022 Jan; 42(1):23-33. PubMed ID: 34655497
[TBL] [Abstract][Full Text] [Related]
19. Variability of Voriconazole Trough Levels in Haematological Patients: Influence of Comedications with cytochrome P450(CYP) Inhibitors and/or with CYP Inhibitors plus CYP Inducers.
Cojutti P; Candoni A; Forghieri F; Isola M; Zannier ME; Bigliardi S; Luppi M; Fanin R; Pea F
Basic Clin Pharmacol Toxicol; 2016 Jun; 118(6):474-9. PubMed ID: 26572687
[TBL] [Abstract][Full Text] [Related]
20. Interactive Effects of Glucocorticoids and Cytochrome P450 Polymorphisms on the Plasma Trough Concentrations of Voriconazole.
Jia SJ; Gao KQ; Huang PH; Guo R; Zuo XC; Xia Q; Hu SY; Yu Z; Xie YL
Front Pharmacol; 2021; 12():666296. PubMed ID: 34113252
[No Abstract] [Full Text] [Related]
[Next] [New Search]